NCT00728390 2024-04-22
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Pfizer
Phase 1 Completed
Clinical Trials
17 trialsNCT04511533 2024-04-05
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Pfizer
Phase 4 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT00768664 2021-02-09
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Pfizer
Phase 2 Completed
NCT00553254 2020-10-19
Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
Pfizer
Phase 2 Completed
NCT00548093 2019-05-21
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Pfizer
Phase 2 Completed
NCT01465802 2019-01-09
ARCHER 1042
Pfizer
Phase 2 Completed
NCT00818441 2019-01-08
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Pfizer
Phase 2 Completed
NCT00225121 2018-12-21
Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00728468 2017-08-02
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Pfizer
Phase 1 Completed
NCT01858389 2017-07-18
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT01360554 2017-05-24
ARCHER 1009
Pfizer
Phase 3 Completed
NCT01121575 2015-10-28
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Pfizer
Phase 1 Completed
NCT00769067 2015-10-07
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Pfizer
Phase 2 Completed
NCT00971191 2012-06-22
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804
Pfizer
Phase 1 Terminated
NCT00783328 2011-06-27
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
Pfizer
Phase 1 Completed